ZED1227 shows high potency, with an IC50 of 45 nM and specificity for targeting TG2, but its limitation to cross the blood–brain barrier (BBB) precludes its utility for neurodegenerative diseases [30,211]. Here, TGM2 is linked to neurodegenerative disease.